Summary
- What it does
- MK-677 (Ibutamoren) is used to add lean body mass, improve bone density, and deepen sleep. Reported side effects include more appetite, water retention, higher fasting blood sugar, and a weaker response to insulin; one clinical trial was stopped after serious heart problems in older patients.
- How it works
- A daily pill that copies ghrelin, the hunger hormone. It switches on the same receptor, so the pituitary gland releases more growth hormone and levels of IGF-1, a growth signal made in response to growth hormone, rise. It is not approved, and development appears to have stopped.
- WADA status
- Prohibited by the World Anti-Doping Agency (WADA). Drug-tested athletes cannot use it.
MK-677 (Ibutamoren) is a small molecule studied for its effects on growth hormone, muscle gain, and sleep. Oral ghrelin receptor agonist boosting GH/IGF-1 and sleep quality. Causes insulin resistance and glucose issues. Not FDA-approved, development discontinued.
Ibutamoren (MK-677) is a potent, long-acting, orally-active, selective non-peptide agonist of the ghrelin receptor (GHS-R1a) and growth hormone secretagogue. It mimics ghrelin's action by binding to receptors in the hypothalamus and pituitary gland, increasing growth hormone secretion by 50-97% and significantly elevating IGF-1 levels while preserving natural pulsatile GH secretion patterns. Clinical trials in elderly populations demonstrated significant increases in lean body mass (1.1 kg gain vs 0.5 kg loss with placebo over 12 months), improved bone mineral density, and enhanced markers of bone formation.
Overview
Notable for dramatically improving sleep quality with 20-50% increases in REM sleep and 50% increases in slow-wave sleep.
However, ibutamoren consistently impairs glucose metabolism, causing fasting blood glucose elevation, decreased insulin sensitivity, and increased HbA1c in multiple trials, leading to dose reductions or discontinuation.
One clinical trial was terminated due to serious adverse events including cardiovascular concerns and congestive heart failure cases in elderly patients.
Not FDA-approved and development appears discontinued due to safety concerns, particularly cardiovascular risks and metabolic effects.
Common side effects include increased appetite, water retention, insulin resistance, and potential increased cancer risk from elevated IGF-1.
Recommended 8-12 week cycles at 10-25mg daily, typically taken before bed for sleep benefits.
As a growth hormone secretagogue, it is prohibited by the World Anti-Doping Agency (WADA) both in and out of competition.
Mechanism of action
Oral ghrelin receptor agonist that raises growth hormone and IGF-1. Increases lean mass, bone density, and deep sleep. Causes insulin resistance and elevated blood sugar.
Reported effects
Effects reported in the literature and from preclinical models include:
- Preliminary data have been reported for oral ibutamoren as a growth hormone secretagogue in children with partial growth hormone deficiency. [4] Anecdotal
- A single 10 mg dose was detectable in a male volunteer's hair at 1.3 pg/mg four weeks later, and a user who took 60 capsules of 10 mg over 90 days tested positive at 224 pg/mg. [1] Anecdotal
- Hair concentration data established a minimal detectable dose that supports the interpretation of ibutamoren findings in doping-control hair tests. [1] Anecdotal
- Ibutamoren was among the top five molecules reported in 324 suspected illegal sport-performance products analyzed by 14 laboratories in 13 countries, and the limited quantitative data suggested most samples held active doses with some overdosed. [2] Anecdotal
- A 54-year-old man with recent combined use of ibutamoren and the SARM RAD-140 had an atraumatic splenic rupture that needed embolization and splenectomy, with the compounds named only as speculative contributing factors. [3] Anecdotal
Evidence grades: FDA approvedApproved (non-US)Phase IIIPhase IIPhase IPreclinicalAnecdotal
Dosage and administration
Low dose
- 10-15mg daily (ideal for sleep, longevity, first-time users)
Moderate dose
- 20-25mg daily (clinical trial standard, body recomposition)
High dose
- 30mg+ daily (advanced users, not recommended due to side effects)
Timing
- Before bed: Maximizes sleep benefits, reduces daytime hunger
- Morning: Increases appetite throughout day (useful for bulking)
Cycle duration
- 8-12 weeks recommended, up to 16 weeks for intermediate
Half
- life: 24 hours (once daily dosing sufficient)
General
- Monitor fasting glucose and insulin sensitivity during use
Natty status
MK-677 is classified as not natty. It appears on the WADA prohibited list and is banned by major natural bodybuilding federations.[5] Use of this compound places the athlete in the enhanced category rather than the natural category in competitive contexts.
Research
The peptide has been the subject of 9 studies and reference works collected on this site. Additional bibliography is in § External links below.
Related compounds
Other peptides in this catalogue with overlapping mechanisms or status:
Frequently asked questions
What is MK-677?
Oral ghrelin receptor agonist boosting GH/IGF-1 and sleep quality. Causes insulin resistance and glucose issues. Not FDA-approved, development discontinued.
What is MK-677 used for?
MK-677 (Ibutamoren) is used to add lean body mass, improve bone density, and deepen sleep. Reported side effects include more appetite, water retention, higher fasting blood sugar, and a weaker response to insulin; one clinical trial was stopped after serious heart problems in older patients.
How does MK-677 work?
A daily pill that copies ghrelin, the hunger hormone. It switches on the same receptor, so the pituitary gland releases more growth hormone and levels of IGF-1, a growth signal made in response to growth hormone, rise. It is not approved, and development appears to have stopped.
Is MK-677 natty?
No. MK-677 is classified as not natty. It is prohibited by WADA and banned by most natural bodybuilding federations. Use places an athlete in the enhanced category.
Is MK-677 banned by WADA?
Yes. MK-677 is prohibited by the World Anti-Doping Agency (WADA), so drug-tested athletes cannot use it. Check the current WADA Prohibited List before competing.
How is MK-677 administered?
MK-677 is typically administered via: oral. Dosage and administration protocols vary; see the Dosage section for details.
References
- a b Hair detection study for doping control
- ^ Illegal medicines analysis
- ^ Spontaneous Splenic Rupture in a Patient With Recent Use of Performance-Enhancing Compounds: A Case Report and Literature Review.
- ^ New directions in growth hormone treatment in children. Recent review
- a b World Anti-Doping Agency. (2026). Prohibited List 2026.
External links
- Wikipedia article
- Elderly trial on body composition effects
- Diabetes case report
- Ghrelin pathway therapeutic potential review
- Treatment of Pediatric Growth Hormone Deficiency With Oral Secretagogues Revisited.
- MK-677 Capsules — commercial
This page was last updated on October 5, 2026, at 07:22 (UTC).
Research last reviewed on October 5, 2026.
Text is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply.